Publication | Closed Access
Platelet Activation Induced by a Human Neuroblastoma Tumor Cell Line Is Reduced by Prior Administration of Ticlopidine
33
Citations
0
References
1986
Year
Prior AdministrationImmunologyPlatelet Activation InducedPharmacotherapyPlatelet AggregationGliomaTumor BiologyThrombosisNeuro-oncologyHematologyPlatelet AntagonistVascular BiologyPharmacologySknmc CellsCell BiologyTumor MicroenvironmentThrombopoiesisBlood PlateletHemostasisPlatelet-rich PlasmaMedicineAnticoagulant
Ticlopidine (250 mg twice daily) was administered to human volunteers for seven days and the response of their heparinized platelet-rich plasma to SKNMC (ADP-dependent) human neuroblastoma cells was examined. The first wave of platelet aggregation, characteristic of ADP-dependent human tumor cell lines, was completely abolished but was replaced by a lag period prior to the onset of aggregation. In the Baumgartner perfusion apparatus there was a marked inhibition in the thrombus generated by the presence of SKNMC cells with a concomitant increase in the percentage of surface coverage. These results suggest that the administration of ticlopidine could be useful to prevent some of the steps of metastatic dissemination in which activated platelets may play a role.